000166614 001__ 166614
000166614 005__ 20240229133525.0
000166614 0247_ $$2doi$$a10.1016/j.radonc.2020.12.024
000166614 0247_ $$2pmid$$apmid:33359662
000166614 0247_ $$2ISSN$$a0167-8140
000166614 0247_ $$2ISSN$$a1879-0887
000166614 0247_ $$2altmetric$$aaltmetric:96597031
000166614 037__ $$aDKFZ-2020-03050
000166614 041__ $$aeng
000166614 082__ $$a610
000166614 1001_ $$0P:(DE-HGF)0$$aAkbaba, Sati$$b0
000166614 245__ $$aTreatment outcomes of elderly salivary gland cancer patients undergoing radiotherapy - results from a large multicenter analysis.
000166614 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2021
000166614 3367_ $$2DRIVER$$aarticle
000166614 3367_ $$2DataCite$$aOutput Types/Journal article
000166614 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1675086557_20049
000166614 3367_ $$2BibTeX$$aARTICLE
000166614 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000166614 3367_ $$00$$2EndNote$$aJournal Article
000166614 500__ $$aVolume 156, March 2021, Pages 266-274 / #LA:E055#
000166614 520__ $$aTo evaluate oncological outcomes and treatment-related toxicities of elderly salivary gland cancer patients undergoing (chemo)radiotherapy.Local/locoregional control (LRC), progression-free survival (PFS) and overall survival (OS) of elderly patients ≥65 years with primary salivary gland cancers undergoing (chemo)radiotherapy between 2005 and 2020 at three tertiary cancer centers were calculated. The impact of clinicopathological and treatment parameters on outcomes were analyzed, and acute and chronic toxicities were quantified.288 elderly salivary gland cancer patients were included in this multicenter analysis, and their median LRC, PFS and OS amounted to 113, 39 and 75 months, respectively. Age, performance status, comorbidities, definitive vs. adjuvant (chemo)radiotherapy as well as locally/locoregionally advanced cancers and distant metastases correlated with reduced outcomes in elderly salivary gland patients. Patients receiving dose-escalated radiotherapy (total doses >70 GyEQD2) with carbon ion boost radiation resulted in improved LRC, but no improvements in PFS or OS. Concomitant chemoradiotherapy did not improve treatment outcomes in elderly salivary gland carcinoma patients. Radiotherapy of elderly salivary gland cancer patients resulted in moderate higher-grade toxicities despite dose escalation with 70 (24.3%) and 48 patients (16.7%) experiencing acute and chronic grade 3 toxicities, respectively. No grade 4/5 toxicities were observed in this patient cohort.Data from the largest multicenter analysis of elderly salivary gland cancer patients undergoing (chemo)radiotherapy demonstrate favorable LRC and tolerable toxicity rates. Decision-making for these vulnerable patients should be based on patient performance rather than chronological patient age.
000166614 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000166614 588__ $$aDataset connected to CrossRef, PubMed,
000166614 650_7 $$2Other$$aChemotherapy
000166614 650_7 $$2Other$$aElderly patients
000166614 650_7 $$2Other$$aGeriatric patients
000166614 650_7 $$2Other$$aHead-and-neck cancer
000166614 650_7 $$2Other$$aRadiotherapy
000166614 650_7 $$2Other$$aSalivary gland cancer
000166614 7001_ $$0P:(DE-He78)80e100a16534f5fc67f7436ee67a47f9$$aRühle, Alexander$$b1
000166614 7001_ $$aRothhaar, Sofie$$b2
000166614 7001_ $$0P:(DE-HGF)0$$aZamboglou, Constantinos$$b3
000166614 7001_ $$0P:(DE-HGF)0$$aGkika, Eleni$$b4
000166614 7001_ $$aFoerster, Robert$$b5
000166614 7001_ $$0P:(DE-HGF)0$$aOebel, Laura$$b6
000166614 7001_ $$0P:(DE-HGF)0$$aKlodt, Tristan$$b7
000166614 7001_ $$0P:(DE-HGF)0$$aSchmidberger, Heinz$$b8
000166614 7001_ $$0P:(DE-HGF)0$$aGrosu, Anca-Ligia$$b9
000166614 7001_ $$aDebus, Jürgen$$b10
000166614 7001_ $$0P:(DE-He78)a9a6232a4fccf84da58752c9cc24be23$$aBostel, Tilman$$b11
000166614 7001_ $$0P:(DE-He78)8d52e7ff1ccaac7dbf0232fdcb0168bd$$aNicolay, Nils H$$b12$$eLast author
000166614 773__ $$0PERI:(DE-600)1500707-8$$a10.1016/j.radonc.2020.12.024$$gp. S0167814020312500$$p266-274$$tRadiotherapy and oncology$$v156$$x0167-8140$$y2021
000166614 909CO $$ooai:inrepo02.dkfz.de:166614$$pVDB
000166614 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000166614 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)80e100a16534f5fc67f7436ee67a47f9$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000166614 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000166614 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000166614 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000166614 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000166614 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000166614 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000166614 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a9a6232a4fccf84da58752c9cc24be23$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000166614 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d52e7ff1ccaac7dbf0232fdcb0168bd$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000166614 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000166614 9130_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000166614 9141_ $$y2021
000166614 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2020-09-09$$wger
000166614 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-09-09
000166614 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-09-09
000166614 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-09-09
000166614 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-09-09
000166614 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-09-09
000166614 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-09-09
000166614 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-09-09
000166614 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-09-09
000166614 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-09-09
000166614 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bRADIOTHER ONCOL : 2018$$d2020-09-09
000166614 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-09-09
000166614 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-09-09
000166614 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bRADIOTHER ONCOL : 2018$$d2020-09-09
000166614 9202_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Molekulare Radioonkologie$$x0
000166614 9201_ $$0I:(DE-He78)FM01-20160331$$kFM01$$lDKTK FM zentral$$x0
000166614 9201_ $$0I:(DE-He78)FR01-20160331$$kFR01$$lDKTK FR zentral$$x1
000166614 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000166614 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x3
000166614 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Molekulare Radioonkologie$$x4
000166614 980__ $$ajournal
000166614 980__ $$aVDB
000166614 980__ $$aI:(DE-He78)FM01-20160331
000166614 980__ $$aI:(DE-He78)FR01-20160331
000166614 980__ $$aI:(DE-He78)HD01-20160331
000166614 980__ $$aI:(DE-He78)E050-20160331
000166614 980__ $$aI:(DE-He78)E055-20160331
000166614 980__ $$aUNRESTRICTED